The company is focused on the clinical development and commercial exploitation through partnering of its highly innovative antimicrobial drugs and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.
Please contact us at email@example.com to start a discussion.
The company has already completed one collaboration with China Medical Systems signed in 2017 who have rights to the XF platform for Greater China and related territories.
- 10 Sep 2019 – Destiny Pharma to attend IDWeek 2019, 2 – 6 October 2019, in Washington DC, USA 10/09/2019
- 10 Sep 2019 – Destiny Pharma to attend CPhI Europe, 5 – 7 November 2019, in Frankfurt, Germany 10/09/2019
- 10 Sep 2019 – Destiny Pharma to attend BIO-Europe 2019, 11 – 13 November 2019, in Hamburg, Germany 10/09/2019